Louis Cantilena, Jr., M.D, Ph.D.

Studies associated with:
Division Study Number Title Investigator(s) Release Date
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D.